Zevra Therapeutics, Inc. (ZVRA) Free cash flow 2016–2025
Zevra Therapeutics, Inc. (ZVRA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$2.4MFY2025 · since FY2016: -$30.4M → -$2.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$2.4M | +96.5% |
| FY2024 | -$69.7M | -105.9% |
| FY2023 | -$33.8M | -79.9% |
| FY2022 | -$18.8M | -282.0% |
| FY2021 | $10.3M | +624.2% |
| FY2020 | -$2.0M | +91.7% |
| FY2019 | -$23.8M | +56.2% |
| FY2018 | -$54.2M | -62.9% |
| FY2017 | -$33.3M | -9.4% |
| FY2016 | -$30.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ZVRA financial trends
ZVRA RevenueZVRA Net incomeZVRA Net marginZVRA Gross profitZVRA Gross marginZVRA Operating incomeZVRA Operating marginZVRA Operating cash flowZVRA Capital expendituresZVRA Return on equityZVRA Stock buybacksZVRA Dividends paidZVRA Total assetsZVRA Total liabilitiesZVRA Shareholders’ equityZVRA overview →